Virus-encoded B7-2 costimulation molecules enhance the protective capacity of a replication-defective herpes simplex virus type 2 vaccine in immunocompetent mice

Journal of Virology

Volumn 83, Issue 2, 2009, Pages 953-960

  Vagvala, Sri P ^a   Thebeau, Lydia G ^a   Wilson, Saydra R ^a   Morrison, Lynda A ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD86 ANTIGEN; GAMMA INTERFERON; HERPES SIMPLEX VACCINE;

ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; IMMUNOCOMPETENCE; IMMUNOSTIMULATION; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VAGINA MUCOSA; VAGINITIS; VIRUS REPLICATION; WILD TYPE;

ANIMALS; ANTIGENS, CD86; CD4-POSITIVE T-LYMPHOCYTES; CENTRAL NERVOUS SYSTEM DISEASES; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HERPESVIRUS VACCINES; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; MUCOUS MEMBRANE; SURVIVAL ANALYSIS; VAGINA;

ANIMALIA; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2; MUS; REPLICATION DEFECTIVE VIRUSES; SIMPLEXVIRUS;

EID: 58149526764     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.02022-08     Document Type: Article

References (41)

1. Bertram, E. M., W. Dawicki, and T. H. Watts. 2004. Role of T cell costimulation in anti-viral immunity. Semin. Immunol. 16:185-196.
2. + CTL epitope located at the transmembrane-cytoplasmic junction. Cell Immunol. 239:113-120.
3. Da Costa, X. J., N. Bourne, L. R. Stanberry, and D. M. Knipe. 1997. Construction and characterization of a replication-defective herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea pig model of genital disease. Virology 232:1-12.
4. Dudek, T., and D. M. Knipe. 2006. Replication-defective viruses as vaccines and vaccine vectors. Virology 344:230-239.
5. Elloso, M. M., and P. Scott. 1999. Expression and contribution of B7-1 (CD80) and B7-2 (CD86) in the early immune response to Leishmania major infection. J. Immunol. 162:6708-6715.
6. Freeman, G. J., G. S. Gray, C. D. Gimmi, D. B. Lombard, L. J. Zhou, M. White, J. D. Fingeroth, J. G. Gribben, and L. M. Nadler. 1991. Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J. Exp. Med. 174:625-631.
7. Gao, M., and D. M. Knipe. 1989. Genetic evidence for multiple nuclear functions of the herpes simplex virus ICP8 DNA-binding protein. J. Virol. 63:5258-5267.
8. Gaspari, A. A., B. Ferbel, Z. Chen, F. Razvi, and R. Polakowska. 1993. Accessory and alloantigen-presenting cell functions of A431 keratinocytes that stably express the B7 antigen. Cell Immunol. 149:291-302.
9. Greenwald, R. J., G. J. Freeman, and A. H. Sharpe. 2005. The B7 family revisited. Annu. Rev. Immunol. 23:515-548.
10. Harding, F. A., and J. P. Allison. 1993. CD28-B7 interactions allow the induction of CD8 cytotoxic T lymphocytes in the absence of exogenous help. J. Exp. Med. 177:1791-1796.
11. Hathcock, K. S., G. Laszlo, C. Pucillo, P. Linsley, and R. J. Hodes. 1994. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J. Exp. Med. 180:631-640.
12. Janeway, C. A., Jr., and K. Bottomly. 1994. Signals and signs for lymphocyte responses. Cell 76:275-285.
13. Kamali, A., A. J. Nunn, D. W. Mulder, E. Van Dyck, J. G. Dobbins, and J. A. Whitworth. 1999. Seroprevalence and incidence of genital ulcer infections in a rural Ugandan population. Sex. Transm. Infect. 75:98-102.
14. Knipe, D. M., and A. E. Spang. 1982. Definition of a series of stages in the association of two herpesviral proteins with the cell nucleus. J. Virol. 43:314-324.
15. Koelle, D. M., and A. Wald. 2000. Herpes simplex virus: the importance of asymptomatic shedding. J. Antimicrob. Chemother. 45(Suppl. T3):1-8.
16. Lenschow, D. J., A. I. Sperling, M. P. Cooke, G. Freeman, L. Rhee, D. C. Decker, G. Gray, L. M. Nadler, C. C. Goodnow, and J. A. Bluestone. 1994. Differential up-regulation of the B7-1 and B7-2 costimulatory molecules after Ig receptor engagement by antigen. J. Immunol. 153:1990-1997.
17. Marti, W. R., D. Oertli, J. B. Meko, J. A. Norton, and K. Tsung. 1997. Induction of antigen-presenting capacity in tumor cells upon infection with nonreplicating recombinant vaccinia virus encoding murine MHC class II and costimulatory molecules. J. Immunol. Methods 200:191-198.
18. + T lymphocytes in vitro. Cell. Immunol. 179:146-152.
19. McAdam, A. J., E. A. Farkash, B. E. Gewurz, and A. H. Sharpe. 2000. B7 costimulation is critical for antibody class switching and CD8 cytotoxic T-lymphocyte generation in the host response to vesicular stomatitis virus. J. Virol. 74:203-208.
20. + T cells. Immunol. Rev. 165:231-247.
21. Morrison, L. A. 2008. Replication-defective virus vaccine-induced protection of mice from genital herpes simplex virus 2 requires CD4 T cells. Virology 376:205-210.
22. Morrison, L. A., X. J. Da Costa, and D. M. Knipe. 1998. Influence of mucosal and parenteral immunization with a replication-defective mutant of HSV-2 on immune responses and protection from genital challenge. Virology 243:178-187.
23. Morrison, L. A., and D. M. Knipe. 1996. Mechanisms of immunization with a replication-defective mutant of herpes simplex virus 1. Virology 220:402-413.
24. Morrison, L. A., L. Zhu, and L. G. Thebeau. 2001. Vaccine-induced serum immunoglobin contributes to protection from herpes simplex virus type 2 genital infection in the presence of immune T cells. J. Virol. 75:1195-1204.
25. Obasi, A., F. Mosha, M. Quigley, Z. Sekirassa, T. Gibbs, K. Munguti, J. Todd, H. Grosskurth, P. Mayaud, J. Changalucha, D. Brown, D. Mabey, and R. Hayes. 1999. Antibody to herpes simplex virus type 2 as a marker of sexual risk behavior in rural Tanzania. J. Infect. Dis. 179:16-24.
26. Oertli, D., W. R. Marti, J. A. Norton, and K. Tsung. 1996. Non-replicating recombinant vaccinia virus encoding murine B-7 molecules elicits effective costimulation of naive CD4 splenocytes in vitro. J. Gen. Virol. 77:3121-3125.
27. Petrulio, C. A., and H. L. Kaufman. 2006. Development of the PANVAC-VF vaccine for pancreatic cancer. Expert Rev. Vaccines 5:9-19.
28. Schweitzer, A. N., and A. H. Sharpe. 1998. Studies using antigen-presenting cells lacking expression of both B7-1 (CD80) and B7-2 (CD86) show distinct requirements for B7 molecules during priming versus restimulation of Th2 but not Th1 cytokine production. J. Immunol. 161:2762-2771.
29. Shahinian, A., K. Pfeffer, K. P. Lee, T. M. Kundig, K. Kishihara, A. Wakeham, K. Kawai, P. S. Ohashi, C. B. Thompson, and T. W. Mak. 1993. Differential T cell costimulatory requirements in CD28-deficient mice. Science 261:609-612.
30. Sigal, L. J., H. Reiser, and K. L. Rock. 1998. The role of B7-1 and B7-2 costimulation for the generation of CTL responses in vivo. J. Immunol. 161:2740-2745.
31. Stanberry, L. R., S. L. Spruance, A. L. Cunningham, D. I. Bernstein, A. Mindel, S. Sacks, S. Tyring, F. Y. Aoki, M. Slaoui, M. Denis, P. Vandepapeliere, and G. Dubin. 2002. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 347:1652-1661.
32. Suresh, M., J. K. Whitmire, L. E. Harrington, C. P. Larsen, T. C. Pearson, J. D. Altman, and R. Ahmed. 2001. Role of CD28-B7 interactions in generation and maintenance of CD8 T cell memory. J. Immunol. 167:5565-5573.
33. Thebeau, L. G., and L. A. Morrison. 2002. B7 costimulation plays an important role in protection from herpes simplex virus type 2-mediated pathology. J. Virol. 76:2563-2566.
34. Thebeau, L. G., and L. A. Morrison. 2003. Mechanism of reduced T-cell effector functions and class-switched antibody responses to herpes simplex virus type 2 in the absence of B7 costimulation. J. Virol. 77:2426-2435.
35. Thebeau, L. G., S. P. Vagvala, Y. M. Wong, and L. A. Morrison. 2007. B7 costimulation molecules expressed from the herpes simplex virus 2 genome rescue immune induction in B7-deficient mice. J. Virol. 81:12200-12209.
36. Todo, T., R. L. Martuza, M. J. Dallman, and S. D. Rabkin. 2001. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity. Cancer Res. 61:153-161.
37. Williams, I. R., R. J. Ort, and T. S. Kupper. 1994. Keratinocyte expression of B7-1 in transgenic mice amplifies the primary immune response to cutaneous antigens. Proc. Natl. Acad. Sci. USA 91:12780-12784.
38. + T-cell responses. Curr. Biol. 4:499-505.
39. Xu, F., M. R. Sternberg, B. J. Kottiri, G. M. McQuillan, F. K. Lee, A. J. Nahmias, S. M. Berman, and L. E. Markowitz. 2006. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 296:964-973.
40. Zajac, P., A. Schutz, D. Oertli, C. Noppen, C. Schaefer, M. Heberer, G. C. Spagnoli, and W. R. Marti. 1998. Enhanced generation of cytotoxic T lymphocytes using recombinant vaccinia virus expressing human tumor-associated antigens and B7 costimulatory molecules. Cancer Res. 58:4567-4571.
41. Zimmermann, C., P. Seiler, P. Lane, and R. M. Zinkernagel. 1997. Antiviral immune responses in CTLA4 transgenic mice. J. Virol. 71:1802-1807.